{"id":"taxotere-epirubicin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea and vomiting"},{"rate":"5-20%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Mucositis"},{"rate":"1-10%","effect":"Cardiotoxicity"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:04:12.236880","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Taxotere, a semisynthetic derivative of paclitaxel, exerts its antineoplastic effects by binding to the beta subunit of tubulin, thereby stabilizing microtubule dynamics and preventing their disassembly. This leads to the accumulation of microtubules in the mitotic spindle, causing cell cycle arrest at the G2/M phase and triggering apoptosis in rapidly dividing cancer cells. Epirubicin, on the other hand, is an anthracycline antibiotic that intercalates DNA, thereby inhibiting the synthesis of nucleic acids and inducing apoptosis in cancer cells.","oneSentence":"Taxotere works by inhibiting microtubule formation in the mitotic spindle, resulting in cell cycle arrest at the G2/M phase, and ultimately inducing apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:54.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of node-positive breast cancer"},{"name":"Advanced breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"}]},"_fixedFields":["pubmed(10)"],"trialDetails":[{"nctId":"NCT00066443","phase":"PHASE1, PHASE2","title":"Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":93},{"nctId":"NCT00911911","phase":"NA","title":"Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2007-02-22","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT07441460","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-03-07","conditions":"Resectable HER2-positive Breast Cancer","enrollment":1800},{"nctId":"NCT07162051","phase":"PHASE2","title":"A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-03-03","conditions":"HR+/HER2- Early Breast Cancer","enrollment":28},{"nctId":"NCT07410559","phase":"PHASE2","title":"Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-07-01","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT03879577","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-25","conditions":"Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT04290793","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2020-03-01","conditions":"Breast Cancer","enrollment":113},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT06107673","phase":"PHASE2","title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-09-30","conditions":"Breast Cancer","enrollment":144},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT01710176","phase":"PHASE3","title":"Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06-01","conditions":"Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults","enrollment":550},{"nctId":"NCT00462696","phase":"NA","title":"MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2006-02","conditions":"Breast Cancer","enrollment":16},{"nctId":"NCT00872625","phase":"PHASE1","title":"Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-04","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT05900206","phase":"PHASE2","title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-10-26","conditions":"Breast Cancer","enrollment":370},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT02455141","phase":"PHASE3","title":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-03","conditions":"Breast Neoplasm","enrollment":786},{"nctId":"NCT01354522","phase":"PHASE3","title":"TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2011-05","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT06955702","phase":"NA","title":"Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients","status":"RECRUITING","sponsor":"University of Salamanca","startDate":"2023-11-15","conditions":"Breast Neoplasms, Alopecia, Madarosis","enrollment":120},{"nctId":"NCT03201861","phase":"PHASE3","title":"Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2017-07-27","conditions":"Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast","enrollment":762},{"nctId":"NCT01779206","phase":"PHASE2, PHASE3","title":"ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-05","conditions":"Breast Cancer","enrollment":4936},{"nctId":"NCT06768931","phase":"PHASE2","title":"Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-30","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer","enrollment":192},{"nctId":"NCT05296746","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer","status":"RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-05-03","conditions":"Breast Cancer Stage II","enrollment":1100},{"nctId":"NCT05024734","phase":"PHASE2","title":"Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids","status":"RECRUITING","sponsor":"Roland Seiler-Blarer","startDate":"2023-02-21","conditions":"Bladder Cancer, Non-muscle Invasive","enrollment":34},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT06795503","phase":"PHASE3","title":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-02","conditions":"Triple-negative Breast Cancer","enrollment":1462},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT00798070","phase":"PHASE3","title":"Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2007-02","conditions":"Breast Cancer","enrollment":2017},{"nctId":"NCT05165225","phase":"PHASE2","title":"Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-07-13","conditions":"Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer","enrollment":48},{"nctId":"NCT02339532","phase":"PHASE2","title":"Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-01","conditions":"Breast Cancer","enrollment":86},{"nctId":"NCT03013504","phase":"PHASE3","title":"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients","status":"COMPLETED","sponsor":"Prestige Biopharma Limited","startDate":"2018-02-19","conditions":"HER2 Positive Breast Cancer","enrollment":503},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT06470633","phase":"PHASE2","title":"To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-01","conditions":"Breast Cancer, HR+/HER2- Breast Cancer","enrollment":29},{"nctId":"NCT05474690","phase":"PHASE3","title":"A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer","status":"WITHDRAWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-11","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":"Breast Cancer","enrollment":762},{"nctId":"NCT06227065","phase":"PHASE2","title":"Precise Neoadjuvant Chemoresection of Low Grade NMIBC","status":"NOT_YET_RECRUITING","sponsor":"University of Bern","startDate":"2024-10","conditions":"Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low-risk","enrollment":28},{"nctId":"NCT02641847","phase":"PHASE2, PHASE3","title":"TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2016-01","conditions":"Triple Negative Breast Cancer, Breast Cancer","enrollment":503},{"nctId":"NCT03609047","phase":"PHASE2","title":"Adjuvant Palbociclib in Elderly Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-06-14","conditions":"Breast Cancer Stage II, Breast Cancer Stage III","enrollment":366},{"nctId":"NCT05978648","phase":"PHASE2","title":"Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy","status":"RECRUITING","sponsor":"wang shusen","startDate":"2023-09-20","conditions":"Breast Neoplasms","enrollment":116},{"nctId":"NCT00525759","phase":"PHASE2","title":"Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-07","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT05985187","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-10-20","conditions":"HER2-positive Breast Cancer","enrollment":412},{"nctId":"NCT05931042","phase":"","title":"Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review","status":"COMPLETED","sponsor":"Rawalpindi Medical College","startDate":"2023-06-01","conditions":"HER2+ Breast Cancer","enrollment":1209},{"nctId":"NCT05883852","phase":"PHASE3","title":"EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-07","conditions":"HER2 Positive Early Breast Cancer","enrollment":1406},{"nctId":"NCT05914753","phase":"NA","title":"Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2023-07-01","conditions":"Breast Cancer, Chemotherapy Effect","enrollment":200},{"nctId":"NCT05901428","phase":"PHASE3","title":"TCb vs EC-T in High Risk ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":1736},{"nctId":"NCT05871918","phase":"PHASE3","title":"A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-10-08","conditions":"HER-2 Positive Breast Cancer","enrollment":832},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT00432172","phase":"PHASE2","title":"Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2007-04-24","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT00841828","phase":"PHASE2","title":"Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2009-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT00129935","phase":"PHASE3","title":"EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2004-02","conditions":"Breast Cancer","enrollment":1384},{"nctId":"NCT02067416","phase":"PHASE2","title":"PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer","status":"WITHDRAWN","sponsor":"Jenny C. Chang, MD","startDate":"2012-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT05661656","phase":"NA","title":"Catheter Guided Chemo-infusion in Breast Cancer","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-04","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT05636644","phase":"","title":"Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Mei Zhang","startDate":"2022-11-04","conditions":"Breast Cancer","enrollment":112},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT02549677","phase":"PHASE4","title":"Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2015-10","conditions":"Breast Neoplasms","enrollment":294},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours","enrollment":377},{"nctId":"NCT03154749","phase":"PHASE2","title":"DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2016-09-01","conditions":"Triple-Negative Breast Cancer","enrollment":93},{"nctId":"NCT05483439","phase":"PHASE2","title":"A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2021-10-20","conditions":"Stage II-III Breast Cancer","enrollment":100},{"nctId":"NCT05420454","phase":"PHASE4","title":"A Study for the Neoadjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":1576},{"nctId":"NCT05420467","phase":"PHASE4","title":"A Study for the Adjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":2413},{"nctId":"NCT00496795","phase":"PHASE2","title":"Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Bergen","startDate":"2007-09","conditions":"Stage III Breast Cancer AJCC V7","enrollment":100},{"nctId":"NCT01966471","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-31","conditions":"Breast Cancer","enrollment":1846},{"nctId":"NCT05400993","phase":"PHASE2","title":"Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT00248703","phase":"PHASE2","title":"Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2003-10","conditions":"Breast Cancer","enrollment":1128},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT04836156","phase":"PHASE1, PHASE2","title":"Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2021-04-02","conditions":"HER2-negative Early Breast Cancer","enrollment":46},{"nctId":"NCT01929811","phase":"PHASE2","title":"NeoMET Study in Neoadjuvant Treatment of Breast Cancer","status":"TERMINATED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2013-10","conditions":"pCR Rate, BCT Rate, Safety","enrollment":92},{"nctId":"NCT05287308","phase":"NA","title":"Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study","status":"NOT_YET_RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-03","conditions":"Breast Cancer","enrollment":500},{"nctId":"NCT02400567","phase":"PHASE2","title":"Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-01","conditions":"Neoadjuvant Operable Breast Cancer","enrollment":125},{"nctId":"NCT05253066","phase":"PHASE2, PHASE3","title":"Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2022-02-25","conditions":"Breast Neoplasms","enrollment":130},{"nctId":"NCT05251766","phase":"PHASE1","title":"Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer","status":"UNKNOWN","sponsor":"Xuli Meng","startDate":"2022-04-20","conditions":"Breast Cancer, Chemotherapy Effect","enrollment":30},{"nctId":"NCT03243838","phase":"PHASE2","title":"Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2018-08-01","conditions":"Triple-Negative Breast Cancer","enrollment":31},{"nctId":"NCT04059003","phase":"","title":"CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2019-11-01","conditions":"Breast Neoplasms","enrollment":200},{"nctId":"NCT04929548","phase":"PHASE4","title":"Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP","status":"NOT_YET_RECRUITING","sponsor":"Wuhan University","startDate":"2022-01-05","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT02468739","phase":"PHASE3","title":"Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT00193050","phase":"PHASE2","title":"Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2001-11","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT00464646","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2007-05","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT03894007","phase":"PHASE2","title":"Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer","status":"TERMINATED","sponsor":"Renske Altena","startDate":"2019-05-23","conditions":"Early-stage Breast Cancer, HER2-positive Breast Cancer","enrollment":6},{"nctId":"NCT02132949","phase":"PHASE2","title":"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-14","conditions":"Breast Cancer","enrollment":401},{"nctId":"NCT04576143","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-09-20","conditions":"HER2-negative Breast Cancer, Neoadjuvant Chemotherapy","enrollment":260},{"nctId":"NCT04137640","phase":"PHASE4","title":"Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2021-07-19","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT04136782","phase":"PHASE4","title":"Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2021-07-19","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT04717531","phase":"PHASE2","title":"Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-06-03","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT02909751","phase":"PHASE2","title":"Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2016-09-14","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT03983538","phase":"","title":"Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2015-06-02","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT04829890","phase":"","title":"Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2004-02","conditions":"Breast Cancer, Adenocarcinoma of Breast","enrollment":89},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT02324088","phase":"PHASE3","title":"Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2000-10","conditions":"Inflammatory Breast Cancer","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"recentPublications":[{"date":"2019 Jul 17","pmid":"31319484","title":"Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study.","journal":"Nutrients"},{"date":"2017 Mar","pmid":"28454303","title":"Expression of ERβ gene in breast carcinoma and the relevance in neoadjuvant therapy.","journal":"Oncology letters"},{"date":"2015 Feb","pmid":"25480315","title":"Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer.","journal":"Cancer chemotherapy and pharmacology"},{"date":"2014 Oct-Dec","pmid":"26842203","title":"The outcome effect of double-hormonal therapy in premenopausal breast cancer patients with high nodal-status: Result of a prospective randomized trial.","journal":"Indian journal of cancer"},{"date":"2011 Oct","pmid":"21997525","title":"[Primary systemic therapy in breast cancer patients (2007-2010)].","journal":"Magyar sebeszet"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Taxotere , Epirubicin","genericName":"Taxotere , Epirubicin","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Taxotere works by inhibiting microtubule formation in the mitotic spindle, resulting in cell cycle arrest at the G2/M phase, and ultimately inducing apoptosis in cancer cells. Used for Adjuvant treatment of node-positive breast cancer, Advanced breast cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}